Increased expression of SRp40 affecting CD44 splicing is associated with the clinical outcome of lymph node metastasis in human breast cancer

Clinica Chimica Acta

Volumn 384, Issue 1-2, 2007, Pages 69-74

  Huang, Chiun Sheng ^a   Shen, Chen Yang ^b,c   Wang, Hsiao Wei ^b   Wu, Pei Ei ^b   Cheng, Chun Wen ^b,d  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^c ACADEMIA SINICA   (Taiwan)

^d CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Breast cancer; CD44; Lymph node metastasis; Pre mRNA splicing; SR

Indexed keywords

ARGININE; CD44V ANTIGEN; PROTEIN P40; SERINE;

ADULT; ARTICLE; BREAST CANCER; CANCER TISSUE; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; GENE EXPRESSION; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY ANALYSIS; STATISTICAL ANALYSIS; TUMOR CELL;

ADULT; AGED; AGED, 80 AND OVER; ALTERNATIVE SPLICING; ANTIGENS, CD44; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; NUCLEAR PROTEINS; PROGNOSIS; RISK; RNA-BINDING PROTEINS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 34547842168     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2007.06.001     Document Type: Article

References (39)

1. Fearon E.R., and Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 61 (1990) 759-767
2. Loeb L.A. Cancer cells exhibit a mutator phenotype. Adv Cancer Res 72 (1998) 25-56
3. Bielas J.H., and Loeb L.A. Mutator phenotype in cancer: timing and perspectives. Environ Mol Mutagen 45 (2005) 206-213
4. Bignold L.P. The mutator phenotype theory can explain the complex morphology and behaviour of cancers. Cell Mol Life Sci 59 (2002) 950-958
5. Manley J.L., and Tacke R. SR proteins and splicing control. Genes Dev 10 (1996) 1569-1579
6. Valcarcel J., and Green M.R. The SR protein family: pleiotropic functions in pre-mRNA splicing. Trends Biochem Sci 21 (1996) 296-301
7. Sanford J.R., Ellis J., and Caceres J.F. Multiple roles of arginine/serine-rich splicing factors in RNA processing. Biochem Soc Trans 33 (2005) 443-446
8. Zahler A.M., Lane W.S., Stolk J.A., and Roth M.B. SR proteins: a conserved family of pre-mRNA splicing factors. Genes Dev 6 (1992) 837-847
9. Screaton G.R., Caceres J.F., Mayeda A., et al. Identification and characterization of three members of the human SR family of pre-mRNA splicing factors. EMBO J 14 (1995) 4336-4349
10. Caceres J.F., Misteli T., Screaton G.R., Spector D.L., and Krainer A.R. Role of the modular domains of SR proteins in subnuclear localization and alternative splicing specificity. J Cell Biol 138 (1997) 225-238
11. Qi J., Su S., McGuffin M.E., and Mattox W. Concentration dependent selection of targets by an SR splicing regulator results in tissue-specific RNA processing. Nucleic Acids Res 34 (2006) 6256-6263
12. Zerbe L.K., Pino I., Pio R., et al. Relative amounts of antagonistic splicing factors, hnRNP A1 and ASF/SF2, change during neoplastic lung growth: implications for pre-mRNA processing. Mol Carcinog 41 (2004) 187-196
13. Fischer D.C., Noack K., Runnebaum I.B., et al. Expression of splicing factors in human ovarian cancer. Oncol Rep 11 (2004) 1085-1090
14. Mathioudaki K., Leotsakou T., Papadokostopoulou A., et al. SR-A1, a member of the human pre-mRNA splicing factor family, and its expression in colon cancer progression. Biol Chem 385 (2004) 785-790
15. Venables J.P. Aberrant and alternative splicing in cancer. Cancer Res 64 (2004) 7647-7654
16. Udabage L., Brownlee G.R., Nilsson S.K., and Brown T.J. The over-expression of HAS2, Hyal-2 and CD44 is implicated in the invasiveness of breast cancer. Exp Cell Res 310 (2005) 205-217
17. Wai P.Y., and Kuo P.C. The role of Osteopontin in tumor metastasis. J Surg Res 121 (2004) 228-241
18. Goodison S., Urquidi V., and Tarin D. CD44 cell adhesion molecules. Mol Pathol 52 (1999) 189-196
19. Marhaba R., and Zoller M. CD44 in cancer progression: adhesion, migration and growth regulation. J Mol Histol 35 (2004) 211-231
20. Draffin J.E., McFarlane S., Hill A., Johnston P.G., and Waugh D.J. CD44 potentiates the adherence of metastatic prostate and breast cancer cells to bone marrow endothelial cells. Cancer Res 64 (2004) 5702-5711
21. Imam H., Eriksson B., and Oberg K. Expression of CD44 variant isoforms and association to the benign form of endocrine pancreatic tumours. Ann Oncol 11 (2000) 295-300
22. Montgomery E., Abraham S.C., Fisher C., et al. CD44 loss in gastric stromal tumors as a prognostic marker. Am J Surg Pathol 28 (2004) 168-177
23. Yamada Y., Itano N., Narimatsu H., et al. CD44 variant exon 6 expressions in colon cancer assessed by quantitative analysis using real time reverse transcriptase-polymerase chain reaction. Oncol Rep 10 (2003) 1919-1924
24. Stickeler E., Kittrell F., Medina D., and Berget S.M. Stage-specific changes in SR splicing factors and alternative splicing in mammary tumorigenesis. Oncogene 18 (1999) 3574-3582
25. Stickeler E., Runnebaum I.B., Mobus V.J., Kieback D.G., and Kreienberg R. Expression of CD44 standard and variant isoforms v5, v6 and v7 in human ovarian cancer cell lines. Anticancer Res 17 (1997) 1871-1876
26. Lo Y.L., Yu J.C., Huang C.S., et al. Allelic loss of the BRCA1 and BRCA2 genes and other regions on 17q and 13q in breast cancer among women from Taiwan (area of low incidence but early onset). Int J Cancer 79 (1998) 580-587
27. Cheng T.C., Chen S.T., Huang C.S., et al. Breast cancer risk associated with genotype polymorphism of the catechol estrogen-metabolizing genes: a multigenic study on cancer susceptibility. Int J Cancer 113 (2005) 345-353
28. Shen C.Y., Yu J.C., Lo Y.L., et al. Genome-wide search for loss of heterozygosity using laser capture microdissected tissue of breast carcinoma: an implication for mutator phenotype and breast cancer pathogenesis. Cancer Res 60 (2000) 3884-3892
29. Giovangrandi Y., Parfait B., Asheuer M., et al. Analysis of the human CGB/LHB gene cluster in breast tumors by real-time quantitative RT-PCR assays. Cancer Lett 168 (2001) 93-100
30. Girault I., Lerebours F., Tozlu S., et al. Real-time reverse transcription PCR assay of CYP19 expression: application to a well-defined series of post-menopausal breast carcinomas. J Steroid Biochem Mol Biol 82 (2002) 323-332
31. Konig H., Ponta H., and Herrlich P. Coupling of signal transduction to alternative pre-mRNA splicing by a composite splice regulator. EMBO J 17 (1998) 2904-2913
32. Wielenga V.J., Smits R., Korinek V., et al. Expression of CD44 in Apc and Tcf mutant mice implies regulation by the WNT pathway. Am J Pathol 154 (1999) 515-523
33. Cheng C.W., Wu P.E., Yu J.C., et al. Mechanisms of inactivation of E-cadherin in breast carcinoma: modification of the two-hit hypothesis of tumor suppressor gene. Oncogene 20 (2001) 3814-3823
34. Kopfstein L., and Christofori G. Metastasis: cell-autonomous mechanisms versus contributions by the tumor microenvironment. Cell Mol Life Sci 63 (2006) 449-468
35. Chausovsky A., Bershadsky A.D., and Borisy G.G. Cadherin-mediated regulation of microtubule dynamics. Nat Cell Biol 2 (2000) 797-804
36. Bukholm I.K., Nesland J.M., and Borresen-Dale A.L. Re-expression of E-cadherin, alpha-catenin and beta-catenin, but not of gamma-catenin, in metastatic tissue from breast cancer patients. J Pathol 190 (2000) 15-19
37. Gotte M., and Yip G.W. Heparanase, hyaluronan, and CD44 in cancers: a breast carcinoma perspective. Cancer Res 66 (2006) 10233-10237
38. Kondo Y., and Issa J.P. Epigenetic changes in colorectal cancer. Cancer Metastasis Rev 23 (2004) 29-39
39. Pind M.T., and Watson P.H. SR protein expression and CD44 splicing pattern in human breast tumours. Breast Cancer Res Treat 79 (2003) 75-82